383 related articles for article (PubMed ID: 9771956)
1. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0-polyethylene glycol ester transport form.
Conover CD; Pendri A; Lee C; Gilbert CW; Shum KL; Greenwald RB
Anticancer Res; 1997; 17(5A):3361-8. PubMed ID: 9413173
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
7. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
8. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
9. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
10. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate.
Henne WA; Kularatne SA; Hakenjos J; Carron JD; Henne KL
Bioorg Med Chem Lett; 2013 Nov; 23(21):5810-3. PubMed ID: 24064501
[TBL] [Abstract][Full Text] [Related]
12. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
[TBL] [Abstract][Full Text] [Related]
13. Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin.
Kunii R; Onishi H; Machida Y
Eur J Pharm Biopharm; 2007 Aug; 67(1):9-17. PubMed ID: 17337172
[TBL] [Abstract][Full Text] [Related]
14. Tripartate poly(ethylene glycol) prodrugs of the open lactone form of camptothecin.
Greenwald RB; Zhao H; Xia J
Bioorg Med Chem; 2003 Jun; 11(12):2635-9. PubMed ID: 12757729
[TBL] [Abstract][Full Text] [Related]
15. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors.
Ying V; Haverstick K; Page RL; Saltzman WM
J Biomater Sci Polym Ed; 2007; 18(10):1283-99. PubMed ID: 17939886
[TBL] [Abstract][Full Text] [Related]
17. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
[TBL] [Abstract][Full Text] [Related]
18. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability.
Watanabe M; Kawano K; Yokoyama M; Opanasopit P; Okano T; Maitani Y
Int J Pharm; 2006 Feb; 308(1-2):183-9. PubMed ID: 16324807
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
[TBL] [Abstract][Full Text] [Related]
20. Nanocarrier improves the bioavailability, stability and antitumor activity of camptothecin.
Tang XJ; Han M; Yang B; Shen YQ; He ZG; Xu DH; Gao JQ
Int J Pharm; 2014 Dec; 477(1-2):536-45. PubMed ID: 25445532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]